![Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial - The Lancet Infectious Diseases Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial - The Lancet Infectious Diseases](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/asset/d2335e1d-f156-42f6-a26e-0f8b036693df/gr1.jpg)
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial - The Lancet Infectious Diseases
![PDF] A Review on: Phase '0' Clinical Trials or Exploratory Investigational New Drug | Semantic Scholar PDF] A Review on: Phase '0' Clinical Trials or Exploratory Investigational New Drug | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/158378dda212a22d6c99ca06646d8f900e8cacf0/3-Table1-1.png)
PDF] A Review on: Phase '0' Clinical Trials or Exploratory Investigational New Drug | Semantic Scholar
![Phase I dose-escalation single centre clinical trial to evaluate the safety of infusion of memory T cells as adoptive therapy in COVID-19 (RELEASE) - eClinicalMedicine Phase I dose-escalation single centre clinical trial to evaluate the safety of infusion of memory T cells as adoptive therapy in COVID-19 (RELEASE) - eClinicalMedicine](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/d763732d-acff-446e-872e-e81d6e44f06f/gr1_lrg.jpg)
Phase I dose-escalation single centre clinical trial to evaluate the safety of infusion of memory T cells as adoptive therapy in COVID-19 (RELEASE) - eClinicalMedicine
![PDF) The challenge of ensuring a successful trial design when conducting clinical trials in the context of disease epidemics and the potential strategies that address this PDF) The challenge of ensuring a successful trial design when conducting clinical trials in the context of disease epidemics and the potential strategies that address this](https://www.researchgate.net/profile/Shauna-Lafferty-Dunne/publication/348807437/figure/fig1/AS:984566714085380@1611750405937/Potential-drugs-must-go-through-each-phase-of-clinical-trials-to-be-approved-for-release_Q320.jpg)
PDF) The challenge of ensuring a successful trial design when conducting clinical trials in the context of disease epidemics and the potential strategies that address this
![MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study | Nature Medicine MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study | Nature Medicine](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41591-021-01336-3/MediaObjects/41591_2021_1336_Fig1_HTML.png)